Deborah Telman, Gilead Sciences Inc.'s top lawyer for the past three years, is relinquishing her duties as general counsel ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Deborah Telman is exiting months after the company paid $202 million to settle allegations that it provided illegal kickbacks ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Gilead Sciences (GILD) stock has drawn the attention of investors with its recent performance over the past month, gaining ...

Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Gilead Sciences ( ($GILD) ) has provided an update. On November 19, 2025, Gilead Sciences announced that Deborah H. Telman will step down from her ...

Gilead Sciences recently announced that its Phase 3 ARTISTRY-1 trial met the primary endpoint for a novel single-tablet HIV ...

Gilead Sciences has developed an industry-leading HIV portfolio in recent years with its megablockbuster daily treatment ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

Gilead has reported that its phase 3 ASCENT-07 trial evaluating Trodelvy (sacituzumab govitecan-hziy) as a first-line ...

Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM ESTCompany ParticipantsAndrew Dickinson - Chief ...